| Literature DB >> 28928751 |
Yonggang Zhou1, Xiuxiu Xu1,2, Zhigang Tian1,2, Haiming Wei1,2.
Abstract
For over four decades, our understanding of natural killer (NK) cells has evolved from the original description of cluster of differentiation (CD)56+CD3- to establishing NK cells as an important subset of innate lymphocytes in the host's surveillance against viral infections and malignancy. The progress of research on the fundamental properties and therapeutic prospects for translational medicine using NK cells excites immunologists and clinicians. Over the past decade, numerous advances in "-omics"-scale methods and new technological approaches have addressed many essential questions in the biology of NK cells. We now have further understanding of the overall molecular mechanisms of action that determine the development, function, plasticity, diversity, and immune reactivity of NK cells. These findings are summarized here, and our view on how to study NK cells using "multi-omics" is highlighted. We also describe "-omics" analyses of the relationships between NK cells and viral infection, tumorigenesis, and autoimmune diseases. Ultimately, a deeper and more comprehensive understanding of NK cells in multiple conditions will provide more effective strategies to manipulate NK cells for the treatment of human disease.Entities:
Keywords: natural killer cell diversity; natural killer cell immunotherapy; natural killer cell molecular program; “multi-omics”; “omics” technology
Year: 2017 PMID: 28928751 PMCID: PMC5591885 DOI: 10.3389/fimmu.2017.01095
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1The timeline of NK cell research keeps pace with advances in “-omics” technology. Since the identification of NK cells in 1975, analytical methods for NK cells were based mainly on FCM and gene expression analyses. From 1969 to the present day, rapid technological advances in FCM and gene expression analyses have become high-throughput technologies in the true sense, and there is much hope for the future. The top row shows the timeline of events related to NK cell research. Blue represents NK cells in general, and green denotes mouse NK cells. The bottom row shows the progress of events related to “-omics” technology. NK, natural killer; ADCC, antibody-dependent cell-mediated cytotoxicity; mAb, monoclonal antibody; ILC, innate lymphoid cell; FACS, fluorescence-activated cell sorting; FCM, flow cytometry; PCR, polymerase chain reaction; CFSE, carboxyfluorescein succinimidyl ester; ChIP-seq, chromatin immunoprecipitation sequencing; RNA-seq, RNA sequencing; ATAC-seq, assay for transposase-accessible chromatin sequencing; CRISPR, clustered regularly interspaced short palindromic repeats; LC-MS/MS, liquid chromatography–tandem mass spectrometry. The references cited in this figure are all listed in the data sheet (Supplementary Material).
Application of “Omics technologies” in complex NK cell research.
| Species | Sample | Method | Keypoint | Reference |
|---|---|---|---|---|
| Mo | NK. Sp./Lv./SI. | P: Affymetrix MoGene 1.0 ST array | 1. ILC1. Lv.: CD49a+, TRAIL+ | GSE37448 ( |
| 2. ILC1. SP.: CD127+, Eomes− | ||||
| 3. ILC1. SI.: CD27−, Eomes− | ||||
| ILC1. Sp./Lv./SI. | A: GenePattern; PCA | |||
| Mo | NK. Sp. Healthy | P: Affymetrix MoGene 1.0 ST array | GSE15907 ( | |
| NK. Sp. MCMV | A: GenePattern | |||
| Hu | NK. PB./CB./D. | P: Whole HuGenome Oligo Microarray | 1. Homeobox TFs enrich in dNK | GSE24268 ( |
| A: Agilent’s Feature-Extraction v 9.1.3 | 2. Zinc-finger TFs enrich in pNK; | |||
| Hu | NK. PB./CB./D. | P: Hu miRNA microarray | 1. Inhibitory miRNA: miR-483-3p | GSE66325 ( |
| A: Agilent’s Feature-Extraction v 9.5.3.1 | 2. Activated miRNA: miR-362-5p | |||
| Hu | NK. PB./CB./D. | P: Agilent Hu180K lncRNA and mRNA microarray | Lnc-CD56 upregulates CD56 | ( |
| Mo | CD49a+ NK. Lv./Sp./BM. | P: HiSeq 2500 | 1. trNK: CD49a+, CD69+ | ( |
| DX5+ NK. Lv./Sp./BM. | A: ESAT software | 2. trNK is depend on T-bet | ||
| Hu | ILCs. Tn | L: SMART-seq2 Pro. | 1. Human ILCs express | ( |
| P: HiSeq2000 | ||||
| NK. Tn | A: STAR v2.3.0, SCDE | 2. Mature ILCs including NK cells express PLZF, unlike mice | ||
| Mo | WT. CLP. | L: SMART-seq2 Pro. | PD-1+ ILCP | ( |
| P: HiSeq2000; A: DESeq2, SPADE | ||||
| Mo | NK. Sp. Resting | P: GA (Illumina) seq; SOLiD seq | Inhibitory miRNA: miR-223 | GSE21003 ( |
| NK. Sp. IL-15-activated | A: pipeline v 0.2.2, SHRiMP | |||
| Mo | NK. Sp./Lv. | ATAC-Seq, P: HiSeq 2500 | Regulomes of ILCs VS T cells: | GSE77695 ( |
| ILC1. Lv. | A: MACS v 1.4.2, HOMER v 4.8 | |||
| HSC. BM. | ChIP-Seq, P: HiSeq 2500 | 1. The regulator of the ILC effector genes is easier to open | ||
| CLP. BM. | A: SICER, MACS v 1.4.2 | |||
| NKp. BM. | RNA-seq, P: HiSeq 2000 | 2. Regulomes of ILCs arborize early at precursor stages | ||
| imNK. BM. | A: Cufflinks 2.2.1 | |||
| Hu | NK. CB./PB. Healthy | P: Mass cytometer (Fluidigm) | The increased diversity of NK cells affects the function | ( |
| NK. PB. HIV | A: Inverse Simpson Index | |||
| Hu | NK. PB. | P: Mass cytometer (Fluidigm) | CD49e− trNK in human liver | ( |
| NK. L-PxF. | A: SPADE; Cytobank | |||
| Hu | CD56bright NK. PB. | P: UHPLC, Q Exactive HF | The effect genes of NK and TEM cells are similar | PXD004352 ( |
| CD56dim NK. PB. | A: MaxQuant v1.5.3.2, Communication | |||
| Mo | P: CRISPR | SFRs for NK cell education | ( | |
| A: Sequencing; FACS | ||||
Mo, mouse; Hu, Human; Sp, spleen; Lv, Liver; BM, bone marrow; SI, small intestinal lamina propria; L-PxF, liver postexcision flush; PB, peripheral blood mononuclear cell; CB, cord blood mononuclear cells; D, decidual mononuclear cells; Tn, tonsil; SFRs, signaling lymphocytic activation molecule family receptors library preparation; TFs, transcription factors; HSCs, hemopoietic stem cells; CLP, common lymphoid progenitors; trNK, tissue-resident natural killer; NKp, natural killer cell precursor; imNK, immature natural killer; cNK, conventional natural killer; ILCP, precursors of innate lymphoid cells; L, library preparation; P, platform; A, analysis; Pro., protocol; scRNA-seq, single-cell RNA sequencing; ATAC-Seq, assay for transposase-accessible chromatin sequencing; ChIP-seq, chromatin immunoprecipitation sequencing; CyTOF, cytometry by time of flight; LC-MS/MS, liquid chromatography–tandem mass spectrometry; CRISPR, clustered regularly interspaced short palindromic repeats; SCDE, single-cell differential expression; SPADE, spanning-tree progression analysis of density-normalized events; SICER, Spatial clustering for identification of ChIP-enriched regions; UHPLC, ultra-high performance liquid chromatography; CD, cluster of differentiation; dNK, decidual natural killer; pNK, peripheral natural killer; RNA-seq, RNA sequencing; ILC, innate lymphoid cell; IL, interleukin; ncRNA, non-coding RNA; FACS, fluorescence-activated cell sorting; HIV, human immunodeficiency virus; MCMV, murine cytomegalovirus.
Figure 2“Multi-omics” analyses for the further understanding of NK cells. “Multi-omics” analytical design and key questions to be addressed for NK cells (schematic). NK cells are an important part of the first line of defense for the body. NK cells are present in most of the tissues and organs of humans and mice, including blood, spleen, lymph nodes, bone marrow, liver, lungs, and uterus. NK cells were isolated by flow cytometry and analyzed by various “-omics” technologies in steady and activated states. Just like a prism refracting the seven colors comprising white light, “-omics” and “multi-omics” analyses of the intricate critical problems of NK cells can produce massive amounts of data and a panoramic view by sequencing, mass spectrometry, and LC-MS/MS and could help to solve these problems. There are three major research aspects of NK cells: (i) understanding NK cells from multiple perspectives (“what is a NK cell?”); (ii) the origin and development of NK cells (“where do NK cells come from?”); and (iii) how NK cells may be transformed and applied (“where are NK cells going?”). The knowledge provided by basic research can guide and serve the clinical transformation of NK cells. TF, transcription factor; ADCC, antibody-dependent cell-mediated cytotoxicity; CAR-NK, chimeric antigen receptor-engineered natural killer cell; NK, natural killer cell; ILC, innate lymphoid cell.